Navigation Links
Cantel Medical Reports EPS of $0.38 vs. $0.27 on 9% Sales Increase for Second Quarter Ended January 31, 2013

LITTLE FALLS, N.J., March 7, 2013 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN) reported record net income of $10,452,000, or $0.38 per diluted share, on a 9% increase in sales to a record $106,363,000 for the second quarter ended January 31, 2013. This compares with net income of $7,294,000, or $0.27 per diluted share, on sales of $97,297,000 for the second quarter ended January 31, 2012. For the six months ended January 31, 2013, the Company reported record net income of $20,028,000, or $0.73 per diluted share, on an 8% increase in sales to a record $206,044,000. This compares with net income of $13,514,000, or $0.50 per diluted share, on sales of $190,559,000 for the six months ended January 31, 2012. Results for the second quarter and six months ended January 31, 2013 include $0.02 in net favorable adjustments related to acquisition accounting partially offset by severance and recruiting costs. Results for the second quarter and six months ended January 31, 2012 were inclusive of a $0.02 charge related to an asset impairment.

Andrew Krakauer, Cantel's President and CEO stated, "We are pleased to have delivered record sales and earnings in the second quarter. These positive results confirm the continued success of our three prong approach to growth which includes investing in new product development, sales and marketing programs and acquisitions. All of these strategies positively affected the results this quarter."

Krakauer added, "Performance this quarter was led by our Healthcare Disposables segment. With the benefit of the ongoing integration of the SPS Medical sterility assurance business acquired on November 1, 2012, sales in this segment exceeded the same quarter last year by 36%. Organic sales growth was 11%, about half of which was driven by our distributor customers pulling forward shipments in anticipation of January 1 price increases. Operating profit grew by over 80%, with approximately two thirds of the growth being organic, driven by operating leverage.

As in the first quarter, our Water Purification and Filtration segment had excellent year-over-year quarterly performance with organic sales growth of 15%. Operating profit in the segment grew by 21% due to greater sales of advanced technology products and improved operating efficiencies. Our largest business unit, Endoscopy, had sequential quarterly sales growth of 7%. However, as expected, this segment showed a 2% decline in sales against very strong comparables from the year earlier quarter."

The Company further reported that its balance sheet at January 31, 2013 included current assets of $138,042,000, including cash of $26,825,000, a current ratio of 2.7:1, debt of $107,000,000 and stockholders' equity of $298,002,000.  Krakauer stated, "The Company has a strong balance sheet and continues to generate significant cash flow and EBITDAS.  When compared with the same quarter last year, our EBITDAS grew by 20% to $22,278,000.  After the acquisition of SPS Medical on the first day of the quarter, we were able to reduce net debt by $9 million to $80,175,000."

Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens. 

The Company will hold a conference call to discuss the results for the second quarter ended January 31, 2013 on Thursday, March 7, 2013 at 11:00 AM Eastern Time. To participate in the conference call, dial 1-877-407-8033 approximately 5 to 10 minutes before the beginning of the call. If you are unable to participate, a digital replay of the call will be available from Thursday, March 7, 2013 at 2:00 PM through midnight on May 7, 2013 by dialing 1-877-660-6853 and using conference ID #410008.

The call will be simultaneously broadcast live over the Internet on at A replay of the webcast will be available on Vcall for 90 days.

For further information, visit the Cantel website at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.

 CANTEL MEDICAL CORP. CONDENSED CONSOLIDATED STATEMENTS OF INCOME(In thousands, except per share data)(unaudited)Three Months EndedSix Months EndedJanuary 31,January 31,2013201220132012Net sales$   106,363$
97,297$   206,044$   190,559Cost of sales61,21256,476117,166111,788Gross profit45,15140,82188,87878,771Expenses:  Selling13,72313,27027,13626,193  General and administrative12,38212,09224,43024,194  Research and development2,1832,2984,4774,443Total operating expenses28,28827,66056,04354,830Income before interest, other expense and income taxes

16,86313,16132,83523,941Interest expense7911,0001,4372,031Interest income(16)(24)(29)(54)Other expense-605-605Income before income taxes16,08811,58031,42721,359Income taxes5,6364,28611,3997,845Net income $
3,514Earnings per common share - diluted$
.50Dividends per common share $
.05Weighted average shares - diluted 27,46227,24327,41127,084CANTEL MEDICAL CORP.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(unaudited)January 31,July 31,20132012AssetsCurrent assets$
33,892Property and equipment, net45,78143,022Intangible assets, net76,75571,311Goodwill208,305183,655Other assets2,9752,932$
434,812Liabilities and stockholders' equityCurrent portion of long-term debt$
,000Other current liabilities41,38945,141Long-term debt97,00080,000Other long-term liabilities 25,46723,735Stockholders' equity298,002275,936$
434,812 SUPPLEMENTARY INFORMATIONReconciliation of Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-BasedCompensation Expense ("EBITDAS")(unaudited)The reconciliation of EBITDAS with net income for the three and six months ended January 31, 2013 and 2012,respectively, is as follows (in thousands):Three Months EndedSix Months EndedJanuary 31,January 31,2013201220132012Net income$
3,514Income taxes5,6364,28611,3997,845Interest expense7911,0001,4372,031Interest income(16)(24)(29)(54)Other expense-605-605Depreciation1,8141,7173,5743,394Amortization2,5732,2784,8404,567Loss on disposal of fixed assets993314036EBITDA21,34917,18941,38931,938Stock-based compensation expense9291,3821,8872,313EBITDAS$
34,251EBITDAS is a measure of the Company's performance that is not required by, or presented in accordance with,Generally Accepted Accounting Principles ("GAAP"). EBITDAS is a non-GAAP financial measure defined by theCompany as income before interest, taxes, depreciation, amortization and stock-based compensation expense.The Company believes EBITDAS is an important valuation measurement for management and investors giventhe increasing effect that non-cash charges, such as stock-based compensation, amortization related to acquisitionsand depreciation of capital equipment, has on the Company's net income. In particular, acquisitions have historicallyresulted in significant increases in amortization of intangible assets that reduced the Company's net income.Additionally, the Company regards EBITDAS as a useful measure of operating performance and cash flow beforethe effect of interest expense and complements operating income, net income and other GAAP financial performance measures. Generally, a non-GAAP financial measure is a numerical measure of a Company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. This measure, however, should be considered in addition to, and not as a substitute or superior to, net income, cash flows, or other measures of financial performance prepared in accordance with GAAP. 

SOURCE Cantel Medical Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medical Reports EPS of $0.35 vs. $0.23 for First Quarter Ended October 31, 2012
2. Cantel Medical Appoints Jorgen B. Hansen As Executive Vice President And Chief Operating Officer
3. Cantel Medical Corp. To Present At The CL King 10th Annual Best Ideas Conference
4. Cantel Medical Board Of Directors Authorizes Regular Semiannual Dividend
5. New U.S. Market Data Shows ICU Medicals Needlefree IV Connector Technology Chosen More than Twice as Often as Any Other
6. CCS Medical Announces Agreement with LifeScan
7. Concord Medical to Report Fourth Quarter and Full Year 2012 Financial Results on March 20, 2013
8. Study: Surefire Medicals Technology Improves Delivery Of Embolics In Cancer Treatment
9. Saladax Biomedical Receives $22.4 Million Strategic Equity Investment From Shanghai Fosun Pharmaceutical
10. Leviton Introduces Medical-Grade Power Strips for Use in Patient-Care Areas
11. Varian Medical Systems to Showcase Fast, Reliable, Wireless X-ray Image Detectors at the ECR Annual Meeting in Vienna Next Week
Post Your Comments:
(Date:12/1/2015)... MARIETTA, Ga. , Dec. 1, 2015 ... purchase Dallas, Texas -based Tenet Healthcare,s ... WellStar Board of Trustees approved the strategic move following ... expand upon its proven clinical care models and patient ... improved access to healthcare to new communities. ...
(Date:12/1/2015)...  Eyeon Therapeutics has received a Notice of ... on a charged hydrophilic polymer developed at Particles ... has been shown to be safe and effective ... Mitchnick , MD, CEO states, "This second set ... in conjunction with a therapeutic agent.  Nanoparticles coated ...
(Date:12/1/2015)... Pharma Tech Outlook recently conducted a comprehensive ... Management Solution Providers - 2015 .  After careful consideration ... CIOs, VCs, analysts, and the Pharma Tech Outlook editorial ... 10 clinical data management solution providers (check out the ... 36 respectively). --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates mobile ... wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they are ... of North America (RSNA) 2015 annual meeting through December 3 in Chicago, Illinois, ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... that it has been selected as a finalist in this year’s Fierce Innovation ... FierceMobileHealthcare. Next IT Healthcare was recognized as a finalist in the category of ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Lutronic, ... release of Clarity, the latest addition to the devices for sale in the United ... 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest ... Integration ,” addresses a main “pain point” for merging or aligning healthcare provider ... a deal is signed. This quick-read guidance suggests that failing to recognize ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , ... membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently ... spent a significant amount of time in Sweden since joining PartnerTech based in ...
Breaking Medicine News(10 mins):